|
|
雷替曲塞在消化系统肿瘤中的应用
|
Abstract:
消化系统肿瘤是临床上常见的恶性肿瘤。由于其起病隐匿、进展快，部分患者发现时已经错失手术机会，主要治疗方式为化疗为主的支持治疗。主要化疗药物为5-氟尿嘧啶，但由于5-氟尿嘧啶不良反应多、耐药产生等特点，我们急需探索新型药物改善目前状况。雷替曲塞作为一种新型化疗药物，因其抗肿瘤效果较好，不良反应小而脱颖而出，目前已作为氟尿嘧啶的替代药物广泛应用于治疗不适合5-氟尿嘧啶或亚叶酸钙的晚期结直肠癌患者。近年来，关于雷替曲塞对其他消化系统恶性肿瘤效益的研究也风靡云涌。如何让更多患者在雷替曲塞的治疗中获益，需要明确雷替曲塞是如何发挥抗肿瘤作用的，以及主要运用的领域。本文将讨论雷替曲塞发挥抗肿瘤的机制及其临床应用领域和不良反应，以更好地指导临床实践。
Digestive system tumors are a common clinical malignancy. Due to their insidious onset and rapid progress, some patients have missed the opportunity of surgery when found, and the main treat-ment method is chemotherapy-based supportive therapy. Main chemotherapy drug is 5- fluoroura-cil, but due to its adverse reaction and drug resistance, we urgently need to explore new drugs to improve the current situation. As a new chemotherapeutic drug, realtitrexed stands out because of its good antitumor effect and small adverse effects and it has now been widely used as an alterna-tive to fluorouracil in the treatment of advanced colorectal cancer patients who are not suitable for 5-fluorouracil or leucovorin calcium. In recent years, studies on the benefits of raltitrexed in other digestive malignancies have also become popular. How to enable more patients to benefit from the treatment of raltitrexed needs us to study how raltitrexed plays its antitumor role and the main areas of application. This summarize will discuss the mechanisms by which raltitrexed exerts anti-tumor and its clinical applications and adverse effects to better guide clinical practice.
| [1] | Chen, Y., Wu, J., Cheng, K., et al. (2019) S-1 plus Raltitrexed for Refracto-ry Metastatic Colorectal Cancer: A Phase II Trial. The Oncologist, 24, 591-e165. https://doi.org/10.1634/theoncologist.2018-0901 |
| [2] | Yamashita, K., Kiyonari, S., Tsubota, S., et al. (2020) Thymidylate Syn-thase Inhibitor Raltitrexed Can Induce High Levels of DNA Damage in MYCN-Amplified Neuroblastoma Cells. Cancer Science, 111, 2431-2439.
https://doi.org/10.1111/cas.14485 |
| [3] | Liu, B., Zhu, X., Gao, S., et al. (2019) Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin Post-Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. Journal of Interventional Medicine, 2, 91-96. https://doi.org/10.1016/j.jimed.2019.07.006 |
| [4] | Shao, W., Li, C., Tang, J., et al. (2019) Efficacy and Safety of Raltitrexed plus Oxaliplatin-Based Transarterial Chemoembolization in Patients with Unresectable Hepa-tocellular Carcinoma. Cancer Management and Research, 11, 9863-9869. https://doi.org/10.2147/CMAR.S217524 |
| [5] | Jansson, Y., Graf, W. and Ghanipour, L. (2022) The Prognostic Impact of Lead Times in Colorectal Cancer Patients Undergoing Cytoreductive Surgery and HIPEC. World Journal of Surgical Oncology, 20, 300.
https://doi.org/10.1186/s12957-022-02765-1 |
| [6] | Gong, Q., Song, C., Wang, X., et al. (2020) Hyperthermic Intraperitoneal Chemotherapy with Recombinant Mutant Human TNF-α and Raltitrexed in Mice with Colorectal-Peritoneal Carcinomatosis. Experi-mental Biology and Medicine (Maywood, NJ), 245, 542-551. https://doi.org/10.1177/1535370220905047 |
| [7] | Zeng, L., Liao, Q., Zhao, Q., et al. (2021) Raltitrexed as a Synergistic Hyperthermia Chemotherapy Drug Screened in Patient-Derived Colorectal Cancer Organoids. Cancer Biology & Medicine, 18, 750-762.
https://doi.org/10.20892/j.issn.2095-3941.2020.0566 |
| [8] | Zhou, S., Jiang, Y., Liang, J., et al. (2021) Neoadjuvant Chemotherapy Followed by Hyperthermic Intraperitoneal Chemotherapy for Patients with Colorectal Peritoneal Metastasis: A Retrospective Study of Its Safety and Efficacy. World Journal of Surgical Oncology, 19, 151. https://doi.org/10.1186/s12957-021-02255-w |
| [9] | Guo, J.H., Zhang, H.Y., Gao, S., et al. (2017) Hepatic Artery Infusion with Raltitrexed or 5-Fluorouracil for Colorectal Cancer Liver Metas-tasis. World Journal of Gastroenterology, 23, 1406-1411. https://doi.org/10.3748/wjg.v23.i8.1406 |
| [10] | Yang, X., Li, H., Liu, J., et al. (2021) The Short-Term Efficacy of DEB-TACE Loaded with Epirubicin and Raltitrexed in the Treatment of Intermediate and Ad-vanced Primary Hepatocellular Carcinoma. American Journal of Translational Research, 13, 9562-9569. |
| [11] | Rosch, J.G., Landry, M.R., Thomas, C.R., et al. (2019) Enhancing Chemoradiation of Colorectal Cancer through Targeted Delivery of Raltitrexed by Hyalu-ronic Acid Coated Nanoparticles. Nanoscale, 11, 13947-13960.
https://doi.org/10.1039/C9NR04320A |
| [12] | Rosch, J.G., DuRoss, A.N., Landry, M.R., et al. (2020) Formulation of Fo-late-Modified Raltitrexed-Loaded Nanoparticles for Colorectal Cancer Theranostics. Pharmaceutics, 12, 133. https://doi.org/10.3390/pharmaceutics12020133 |
| [13] | Morey, J., Llinás, P., Bueno-Costa, A., et al. (2021) Raltitrexed-Modified Gold and Silver Nanoparticles for Targeted Cancer Therapy: Cytotoxicity Behavior in Vitro on A549 and HCT-116 Human Cancer Cells. Materials (Basel, Switzerland), 14, 534. https://doi.org/10.3390/ma14030534 |
| [14] | Yan, P., Yin, H., Guo, W., et al. (2020) Raltitrexed versus 5-Fluorouracil with Cisplatin and Concurrent Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma: An Open Labeled, Randomized, Controlled, and Multicenter Clinical Trial. Cancer Medicine, 9, 6166-6172. https://doi.org/10.1002/cam4.3260 |
| [15] | Wu, Y., Wei, X., Yuan, Z., et al. (2020) Phase II Study of Induction Chemotherapy Fol-lowed by Concurrent Chemoradiotherapy with Raltitrexed and Cisplatin in Locally Advanced Nasopharyngeal Carcinoma. Chinese Journal of Cancer Research, 32, 665-672. https://doi.org/10.21147/j.issn.1000-9604.2020.05.11 |
| [16] | Leonardi, M.C., Zampino, M.G., Luca, F., et al. (2006) Pre-Operative Radiochemotherapy with Raltitrexed for Resectable Locally-Advanced Rectal Cancer: A Phase II Study. Anticancer Research, 26, 2419-2423. |
| [17] | Yoney, A., Askaroglu, B., Hancilar, T., et al. (2008) A Retrospective Comparison of Concurrent Bolus 5-Fluorouracil or Raltitrexed in Preoperative Chemoradiation for Locally Advanced Rectal Cancer. Hematology/Oncology and Stem Cell Therapy, 1, 28-33. https://doi.org/10.1016/S1658-3876(08)50057-4 |
| [18] | Royer, B., Schmitt, A., Nguyen, T., et al. (2021) Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity. British Journal of Clinical Pharmacology, 87, 1327-1337. https://doi.org/10.1111/bcp.14519 |
| [19] | Li, Y., Chen, Y., Qiu, C., et al. (2019) 17-Allylamino-17-demethoxygeldanamycin Impeded Chemotherapy through Antioxidant Activation via Reducing Reactive Oxygen Species-Induced Cell Death. Journal of Cellular Biochemistry, 120, 1560-1576. https://doi.org/10.1002/jcb.27397 |
| [20] | 曹淑龙. 雷替曲塞抗结直肠癌的机制及生物学功能研究[D]: [硕士学位论文]. 荆州: 长江大学, 2022. |
| [21] | Huang, X., Ke, K., Jin, W., et al. (2022) Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. Frontiers in Immunology, 13, Article ID: 887048. https://doi.org/10.3389/fimmu.2022.887048 |
| [22] | Blondy, S., David, V., Ver-dier, M., et al. (2020) 5-Fluorouracil Resistance Mechanisms in Colorectal Cancer: From Classical Pathways to Promising Processes. Cancer Science, 111, 3142-3154. https://doi.org/10.1111/cas.14532 |
| [23] | Shiga, T. and Hiraide, M. (2020) Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines. Current Treatment Options in Oncology, 21, 27. https://doi.org/10.1007/s11864-020-0719-1 |
| [24] | Feng, A.W., Guo, J.H., Gao, S., et al. (2022) A Randomized Phase II Trial of Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed versus Oxaliplatin plus 5-Fluorouracil for Unresectable Colorectal Cancer Liver Metastases. Frontiers in Oncology, 12, Article ID: 913017. https://doi.org/10.3389/fonc.2022.913017 |
| [25] | Van Cutsem, E. (1998) Raltitrexed (Tomudex). Expert Opinion on Investigational Drugs, 7, 823-834.
https://doi.org/10.1517/13543784.7.5.823 |
| [26] | Zhao, H., Zhang, Y., Sun, J., et al. (2016) Raltitrexed Inhibits HepG2 Cell Prolif-eration via G0/G1 Cell Cycle Arrest. Oncology Research, 23, 237-248. https://doi.org/10.3727/096504016X14562725373671 |
| [27] | Ding, W.X., Liu, S., Ma, J.X., et al. (2019) Raltitrexed Increases Radiation Sensitivity of Esophageal Squamous Carcinoma Cells. Cancer Cell International, 19, 36. https://doi.org/10.1186/s12935-019-0752-y |
| [28] | Hu, C., Chen, X., Lin, X., et al. (2022) Raltitrexed Regulates Proliferation and Apoptosis of HGC-27 Cells by Upregulating RSK4. BMC Pharmacology & Toxicology, 23, 65. https://doi.org/10.1186/s40360-022-00605-2 |
| [29] | Liang, H., Hu, C., Lin, X., et al. (2020) MiR-548d-3p Promotes Gastric Cancer by Targeting RSK4. Cancer Management and Research, 12, 13325-13337. https://doi.org/10.2147/CMAR.S278691 |
| [30] | Ye, Q., Wang, X., Jin, M., et al. (2018) Effect of RSK4 on Biological Characteristics of Colorectal Cancer. World Journal of Surgical Oncolo-gy, 16, 240. https://doi.org/10.1186/s12957-018-1474-7 |
| [31] | Zhen, H., Li, G., Zhao, P., et al. (2020) Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways. OncoTargets and Therapy, 13, 12325-12339.
https://doi.org/10.2147/OTT.S276125 |
| [32] | K？hne, C.H., Thuss-Patience, P., Friedrich, M., et al. (1998) Raltitrexed (Tomudex): An Alternative Drug for Patients with Colorectal Cancer and 5-Fluorouracil Associated Cardiotoxicity. British Journal of Cancer, 77, 973-977.
https://doi.org/10.1038/bjc.1998.160 |
| [33] | Gallois, C., Hafliger, E., Auclin, E., et al. (2022) First-Line Chemotherapy with Ral-titrexed in Metastatic Colorectal Cancer: An Association des Gastro-Entérologues Oncologues (AGEO) Multicentre Study. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 54, 684-691. https://doi.org/10.1016/j.dld.2021.08.009 |
| [34] | Cucciniello, L., Bidoli, E., Viel, E., et al. (2022) The Puzzling Clinical Presentation of Fluoropyrimidines Cardiotoxicity. Frontiers in Cardiovascular Medicine, 9, Article ID: 960240. https://doi.org/10.3389/fcvm.2022.960240 |
| [35] | Ladak, I., Preti, B., Dias, B., et al. (2022) Raltitrexed as a Substitute for Capecita-bine in Metastatic Gastric Cancer: A Case Report and Literature Review. Annals of Translational Medicine, 10, 1285. https://doi.org/10.21037/atm-2022-69 |
| [36] | Avallone, A., Di Gennaro, E., Silvestro, L., et al. (2014) Targeting Thymidylate Syn-thase in Colorectal Cancer: Critical Re-Evaluation and Emerging Therapeutic Role of Raltitrexed. Expert Opinion on Drug Safety, 13, 113-129.
https://doi.org/10.1517/14740338.2014.845167 |
| [37] | El-Mesallamy, H.O., El Mag-doub, H.M., Chapman, J.M., et al. (2018) Biomolecular Study of Human Thymidylate Synthase Conformer-Selective Inhibitors: New Chemotherapeutic Approach. PLOS ONE, 13, e0193810.
https://doi.org/10.1371/journal.pone.0193810 |
